MANGALAM DRUGS AND ORGANICS LT (MANGALAM): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1YAll

₹29.22 latest close · +4.0% over the last 90 sessions

₹29.22 month-end · +4.6% over 12 months

₹29.22 month-end · −71.8% since Jun '24

52-week range ₹22.80 to ₹66.62 · 1-year volatility 56.2%

How rough has the ride been?

Maximum drawdown-87.5%not yet recovered

1-year volatility56.2%annualised

Drawdown from peak

Largest drawdowns

-87.5% (2021-07 peak to 2025-12 low, not yet recovered)

-71.5% (2019-01 peak to 2020-03 low, recovered 2020-05)

-44.4% (2020-05 peak to 2020-05 low, recovered 2020-08)

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE2nd▼ 22 pts vs a year ago
Op. margin9thflat vs a year ago
Revenue growth3rdflat vs a year ago
EPS growth3rd
Debt/equity ↓6th▼ 9 pts vs a year ago
Cash cycle ↓59th▲ 6 pts vs a year ago
P/E ↓85th
12M momentum48th▲ 47 pts vs a year ago

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

Trailing earnings per share are negative, so a P/E-based figure does not exist. See the loss-makers list on the Expectations Gap page for a revenue-based version.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹29.22
ROCE: -14.0%
Market Cap: ₹46 cr
Revenue (TTM): ₹232 cr
P/S: 0.2x
P/B: 0.4x
ROE: -37.2%
Operating Margin: 1.6%
Debt / Equity: 1.1x
Promoter Holding: 35.6%
12M Momentum: 4.6%

52-week range

₹22.80₹66.62

15% of the way from its 52-week low to its high

Price risk

1Y volatility

56.2%

Beta vs sector

1-year daily

0.47

Balance sheet & cash

Interest cover

operating profit ÷ interest

-1.7x

Share count, 1Y

unchanged

Are profits backed by cash?

1 of 4checks within range1 beyond a threshold

Other income reliance—Not enough data

Not enough reported data to compute this.

Tax rate—Not enough data

Not enough reported data to compute this.

Cash conversion—Not enough data

Not enough reported data to compute this.

Free cash flow1 of 3 yrsBeyond threshold

Fiscal years with positive free cash flow in the last 3: 1. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+27 daysNear threshold

Debtor days are above the median of the previous three fiscal years by 27 days (63 vs 37). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress3% of fixed assetsWithin range

Capital work-in-progress is 3% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+78 days / 2 yrsNear threshold

Days payable changed by +78 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 3 years, promoters trimmed 14.7 pts.
The number of shareholders rose from 17,978 to 24,465 (+36%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change

Promoters50.3%35.6%-14.7 pts

FIIs0.1%0.1%0.0 pts

DIIs———

Public and others49.6%64.2%+14.6 pts

Number of shareholders

24,465shareholders+36% since Sep '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−5.7%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like MANGALAM DRUGS AND ORGANICS LT today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −26% to +45% vs the market, against −2% for all non-financial companies in the same months.
The gap against the base rate (−3.9%, 80% range −10.7% to +7.7%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 4 beyond the range shown, drawn at the edge

Similar setups' median

−5.7%

All companies' median

−1.8%

Beat the market

46% vs 48%

50 past situations · 50 companies · 31 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
PRAKASHSTL Non-Energy Minerals	May 2024	—	-11%	+101%	−43%	−29%
SUPERSPIN Process Industries	Jun 2022	—	-2%	+22%	−49%	−44%
SHAHALLOYS Non-Energy Minerals	Jun 2025	—	-26%	−1%	−43%	+12%
VISACHROME Non-Energy Minerals	Feb 2021	—	-7%	+69%	−26%	+96%
FLEXITUFF Process Industries	Oct 2023	—	-15%	+63%	−19%	+1%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
MADHUCON Industrial Services	Aug 2022	—	-4%	+37%	−49%	−11%
SUPREMEINF Industrial Services	Jul 2023	—	-8%	+32%	−37%	+129%
GILLANDERS Consumer Non-Durables	Jun 2024	—	-8%	+39%	−38%	+43%

How reliable is this?

Matched on P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: interest cover, size and volatility. Not used (unavailable for this company): P/E. This company is loss-making, so it was only compared with loss-making companies. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to MANGALAM DRUGS AND ORGANICS LT. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What changed?

14 events since Mar '20

2026
JunDebtDebt / equity rose above 1.0x (1.10x).
MarPromoterPromoter holding fell 14.7 pts to 35.6%.
2025
DecPriceFell 88% from the Jul 2021 peak to the Dec 2025 low.
SepResultsEPS (TTM) turned negative.
SepPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).
JulPeer rankSlipped to the bottom quartile of Health Technology on ROCE (from the 3rd quartile).
MarPeer rankMoved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
2024
DecResultsEPS (TTM) turned positive.

Show 6 earlier events

2021
JulPriceRegained the 2020-11 peak, 5 months after the low.
FebPriceFell 41% from the Nov 2020 peak to the Feb 2021 low.
2020
AugPriceRegained the 2020-05 peak, 3 months after the low.
MayPriceRegained the 2019-01 peak, 2 months after the low.
MayPriceFell 44% from the May 2020 peak to the May 2020 low.
MarPriceFell 72% from the Jan 2019 peak to the Mar 2020 low.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history30 months · 2024-06 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	—	₹232 cr	-37.2%	-14.0%	1.1x
2026-10	—	₹232 cr	-37.1%	-14.0%	1.1x
2026-09	—	₹232 cr	-37.1%	-14.0%	1.1x
2026-08	—	₹232 cr	-43.1%	-14.0%	1.1x
2026-07	—	₹232 cr	-43.1%	-14.0%	1.1x
2026-06	—	₹232 cr	-43.1%	-14.0%	1.1x
2026-05	—	₹238 cr	-20.8%	8.0%	0.6x
2026-04	—	₹238 cr	-20.8%	8.0%	0.6x
2026-03	—	₹238 cr	-20.8%	8.0%	0.6x
2026-02	—	₹268 cr	-13.3%	8.0%	0.6x
2026-01	—	₹268 cr	-13.3%	8.0%	0.6x
2025-12	—	₹268 cr	-13.3%	8.0%	0.6x
2025-11	—	₹299 cr	-6.6%	8.0%	0.6x
2025-10	—	₹299 cr	-6.6%	8.0%	0.6x
2025-09	—	₹299 cr	-6.6%	8.0%	0.6x
2025-08	17.5x	₹318 cr	4.5%	8.0%	0.6x
2025-07	20.9x	₹318 cr	4.5%	8.0%	0.6x
2025-06	19.0x	₹318 cr	4.5%	8.0%	0.6x
2025-05	12.3x	₹347 cr	7.5%	—	0.8x
2025-04	12.1x	₹347 cr	7.5%	—	0.8x
2025-03	11.5x	₹347 cr	7.5%	—	0.8x
2025-02	15.5x	₹356 cr	6.9%	—	0.8x
2025-01	18.0x	₹356 cr	6.9%	—	0.8x
2024-12	19.4x	₹356 cr	6.9%	—	0.8x
2024-11	—	₹369 cr	-6.6%	—	0.8x
2024-10	—	₹369 cr	-6.6%	—	0.8x
2024-09	—	₹369 cr	-6.6%	—	0.8x
2024-08	—	₹369 cr	-6.6%	—	0.8x
2024-07	—	₹369 cr	-6.6%	—	0.8x
2024-06	—	₹369 cr	-6.6%	—	0.8x

Methodology and data notes